ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock